

Global Sickle Cell Disease Drug Market Growth 2025-2031

<https://marketpublishers.com/r/G113E5261383EN.html>

Date: October 2025

Pages: 126

Price: US\$ 3,660.00 (Single User License)

ID: G113E5261383EN

Abstracts

The global Sickle Cell Disease Drug market size is predicted to grow from US\$ million in 2025 to US\$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the 'Sickle Cell Disease Drug Industry Forecast' looks at past sales and reviews total world Sickle Cell Disease Drug sales in 2024, providing a comprehensive analysis by region and market sector of

projected Sickle Cell Disease Drug sales for 2025 through 2031. With Sickle Cell Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sickle Cell Disease Drug industry.

This Insight Report provides a comprehensive analysis of the global Sickle Cell Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sickle Cell Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Sickle Cell Disease Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sickle Cell Disease Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sickle Cell Disease Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Sickle Cell Disease Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

ARQ-092

BIVV-003

CAL-H

CTX-001

DRX-194

Others

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Acceleron Pharma Inc

Addmedica SAS

Angiocrine Bioscience Inc

Annexin Pharmaceuticals AB

ArQule Inc

Bio Products Laboratory Ltd

Bioverativ Inc

bluebird bio Inc

Bristol-Myers Squibb Co

Calimmune Inc

CRISPR Therapeutics

CSL Ltd

Daiichi Sankyo Co Ltd

Editas Medicine Inc

Errant Gene Therapeutics LLC

Gamida Cell Ltd

Genethon SA

Gilead Sciences Inc

Global Blood Therapeutics Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global Sickle Cell Disease Drug market?

What factors are driving Sickle Cell Disease Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Sickle Cell Disease Drug market opportunities vary by end market size?

How does Sickle Cell Disease Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Sickle Cell Disease Drug Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Sickle Cell Disease Drug by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Sickle Cell Disease Drug by Country/Region, 2020, 2024 & 2031
- 2.2 Sickle Cell Disease Drug Segment by Type
 - 2.2.1 ARQ-092
 - 2.2.2 BIVV-003
 - 2.2.3 CAL-H
 - 2.2.4 CTX-001
 - 2.2.5 DRX-194
 - 2.2.6 Others
- 2.3 Sickle Cell Disease Drug Sales by Type
 - 2.3.1 Global Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Sickle Cell Disease Drug Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Sickle Cell Disease Drug Sale Price by Type (2020-2025)
- 2.4 Sickle Cell Disease Drug Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Others
- 2.5 Sickle Cell Disease Drug Sales by Application
 - 2.5.1 Global Sickle Cell Disease Drug Sale Market Share by Application (2020-2025)

2.5.2 Global Sickle Cell Disease Drug Revenue and Market Share by Application (2020-2025)

2.5.3 Global Sickle Cell Disease Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Sickle Cell Disease Drug Breakdown Data by Company

3.1.1 Global Sickle Cell Disease Drug Annual Sales by Company (2020-2025)

3.1.2 Global Sickle Cell Disease Drug Sales Market Share by Company (2020-2025)

3.2 Global Sickle Cell Disease Drug Annual Revenue by Company (2020-2025)

3.2.1 Global Sickle Cell Disease Drug Revenue by Company (2020-2025)

3.2.2 Global Sickle Cell Disease Drug Revenue Market Share by Company (2020-2025)

3.3 Global Sickle Cell Disease Drug Sale Price by Company

3.4 Key Manufacturers Sickle Cell Disease Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Sickle Cell Disease Drug Product Location Distribution

3.4.2 Players Sickle Cell Disease Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SICKLE CELL DISEASE DRUG BY GEOGRAPHIC REGION

4.1 World Historic Sickle Cell Disease Drug Market Size by Geographic Region (2020-2025)

4.1.1 Global Sickle Cell Disease Drug Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Sickle Cell Disease Drug Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Sickle Cell Disease Drug Market Size by Country/Region (2020-2025)

4.2.1 Global Sickle Cell Disease Drug Annual Sales by Country/Region (2020-2025)

4.2.2 Global Sickle Cell Disease Drug Annual Revenue by Country/Region (2020-2025)

4.3 Americas Sickle Cell Disease Drug Sales Growth

- 4.4 APAC Sickle Cell Disease Drug Sales Growth
- 4.5 Europe Sickle Cell Disease Drug Sales Growth
- 4.6 Middle East & Africa Sickle Cell Disease Drug Sales Growth

5 AMERICAS

- 5.1 Americas Sickle Cell Disease Drug Sales by Country
 - 5.1.1 Americas Sickle Cell Disease Drug Sales by Country (2020-2025)
 - 5.1.2 Americas Sickle Cell Disease Drug Revenue by Country (2020-2025)
- 5.2 Americas Sickle Cell Disease Drug Sales by Type (2020-2025)
- 5.3 Americas Sickle Cell Disease Drug Sales by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Sickle Cell Disease Drug Sales by Region
 - 6.1.1 APAC Sickle Cell Disease Drug Sales by Region (2020-2025)
 - 6.1.2 APAC Sickle Cell Disease Drug Revenue by Region (2020-2025)
- 6.2 APAC Sickle Cell Disease Drug Sales by Type (2020-2025)
- 6.3 APAC Sickle Cell Disease Drug Sales by Application (2020-2025)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Sickle Cell Disease Drug by Country
 - 7.1.1 Europe Sickle Cell Disease Drug Sales by Country (2020-2025)
 - 7.1.2 Europe Sickle Cell Disease Drug Revenue by Country (2020-2025)
- 7.2 Europe Sickle Cell Disease Drug Sales by Type (2020-2025)
- 7.3 Europe Sickle Cell Disease Drug Sales by Application (2020-2025)
- 7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Sickle Cell Disease Drug by Country

8.1.1 Middle East & Africa Sickle Cell Disease Drug Sales by Country (2020-2025)

8.1.2 Middle East & Africa Sickle Cell Disease Drug Revenue by Country (2020-2025)

8.2 Middle East & Africa Sickle Cell Disease Drug Sales by Type (2020-2025)

8.3 Middle East & Africa Sickle Cell Disease Drug Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Sickle Cell Disease Drug

10.3 Manufacturing Process Analysis of Sickle Cell Disease Drug

10.4 Industry Chain Structure of Sickle Cell Disease Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Sickle Cell Disease Drug Distributors

11.3 Sickle Cell Disease Drug Customer

12 WORLD FORECAST REVIEW FOR SICKLE CELL DISEASE DRUG BY GEOGRAPHIC REGION

12.1 Global Sickle Cell Disease Drug Market Size Forecast by Region

12.1.1 Global Sickle Cell Disease Drug Forecast by Region (2026-2031)

12.1.2 Global Sickle Cell Disease Drug Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Sickle Cell Disease Drug Forecast by Type (2026-2031)

12.7 Global Sickle Cell Disease Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Acceleron Pharma Inc

13.1.1 Acceleron Pharma Inc Company Information

13.1.2 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.1.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Acceleron Pharma Inc Main Business Overview

13.1.5 Acceleron Pharma Inc Latest Developments

13.2 Addmedica SAS

13.2.1 Addmedica SAS Company Information

13.2.2 Addmedica SAS Sickle Cell Disease Drug Product Portfolios and Specifications

13.2.3 Addmedica SAS Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 Addmedica SAS Main Business Overview

13.2.5 Addmedica SAS Latest Developments

13.3 Angiocrine Bioscience Inc

13.3.1 Angiocrine Bioscience Inc Company Information

13.3.2 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.3.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 Angiocrine Bioscience Inc Main Business Overview

13.3.5 Angiocrine Bioscience Inc Latest Developments

13.4 Annexin Pharmaceuticals AB

13.4.1 Annexin Pharmaceuticals AB Company Information

13.4.2 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolios and Specifications

13.4.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 Annexin Pharmaceuticals AB Main Business Overview

13.4.5 Annexin Pharmaceuticals AB Latest Developments

13.5 ArQule Inc

13.5.1 ArQule Inc Company Information

13.5.2 ArQule Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.5.3 ArQule Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 ArQule Inc Main Business Overview

13.5.5 ArQule Inc Latest Developments

13.6 Bio Products Laboratory Ltd

13.6.1 Bio Products Laboratory Ltd Company Information

13.6.2 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

13.6.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Bio Products Laboratory Ltd Main Business Overview

13.6.5 Bio Products Laboratory Ltd Latest Developments

13.7 Bioverativ Inc

13.7.1 Bioverativ Inc Company Information

13.7.2 Bioverativ Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.7.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Bioverativ Inc Main Business Overview

13.7.5 Bioverativ Inc Latest Developments

13.8 bluebird bio Inc

13.8.1 bluebird bio Inc Company Information

13.8.2 bluebird bio Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.8.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 bluebird bio Inc Main Business Overview

13.8.5 bluebird bio Inc Latest Developments

13.9 Bristol-Myers Squibb Co

13.9.1 Bristol-Myers Squibb Co Company Information

13.9.2 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolios and Specifications

13.9.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Bristol-Myers Squibb Co Main Business Overview

13.9.5 Bristol-Myers Squibb Co Latest Developments

13.10 Calimmune Inc

13.10.1 Calimmune Inc Company Information

13.10.2 Calimmune Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Calimmune Inc Main Business Overview

13.10.5 Calimmune Inc Latest Developments

13.11 CRISPR Therapeutics

13.11.1 CRISPR Therapeutics Company Information

13.11.2 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolios and Specifications

13.11.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 CRISPR Therapeutics Main Business Overview

13.11.5 CRISPR Therapeutics Latest Developments

13.12 CSL Ltd

13.12.1 CSL Ltd Company Information

13.12.2 CSL Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

13.12.3 CSL Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.12.4 CSL Ltd Main Business Overview

13.12.5 CSL Ltd Latest Developments

13.13 Daiichi Sankyo Co Ltd

13.13.1 Daiichi Sankyo Co Ltd Company Information

13.13.2 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

13.13.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.13.4 Daiichi Sankyo Co Ltd Main Business Overview

13.13.5 Daiichi Sankyo Co Ltd Latest Developments

13.14 Editas Medicine Inc

13.14.1 Editas Medicine Inc Company Information

13.14.2 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolios and

Specifications

13.14.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.14.4 Editas Medicine Inc Main Business Overview

13.14.5 Editas Medicine Inc Latest Developments

13.15 Errant Gene Therapeutics LLC

13.15.1 Errant Gene Therapeutics LLC Company Information

13.15.2 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolios and Specifications

13.15.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.15.4 Errant Gene Therapeutics LLC Main Business Overview

13.15.5 Errant Gene Therapeutics LLC Latest Developments

13.16 Gamida Cell Ltd

13.16.1 Gamida Cell Ltd Company Information

13.16.2 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

13.16.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.16.4 Gamida Cell Ltd Main Business Overview

13.16.5 Gamida Cell Ltd Latest Developments

13.17 Genethon SA

13.17.1 Genethon SA Company Information

13.17.2 Genethon SA Sickle Cell Disease Drug Product Portfolios and Specifications

13.17.3 Genethon SA Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.17.4 Genethon SA Main Business Overview

13.17.5 Genethon SA Latest Developments

13.18 Gilead Sciences Inc

13.18.1 Gilead Sciences Inc Company Information

13.18.2 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolios and Specifications

13.18.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.18.4 Gilead Sciences Inc Main Business Overview

13.18.5 Gilead Sciences Inc Latest Developments

13.19 Global Blood Therapeutics Inc

13.19.1 Global Blood Therapeutics Inc Company Information

13.19.2 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolios and

Specifications

13.19.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)

13.19.4 Global Blood Therapeutics Inc Main Business Overview

13.19.5 Global Blood Therapeutics Inc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Sickle Cell Disease Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Sickle Cell Disease Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of ARQ-092

Table 4. Major Players of BIVV-003

Table 5. Major Players of CAL-H

Table 6. Major Players of CTX-001

Table 7. Major Players of DRX-194

Table 8. Major Players of Others

Table 9. Global Sickle Cell Disease Drug Sales by Type (2020-2025) & (K Pcs)

Table 10. Global Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)

Table 11. Global Sickle Cell Disease Drug Revenue by Type (2020-2025) & (\$ million)

Table 12. Global Sickle Cell Disease Drug Revenue Market Share by Type (2020-2025)

Table 13. Global Sickle Cell Disease Drug Sale Price by Type (2020-2025) & (USD/Pcs)

Table 14. Global Sickle Cell Disease Drug Sale by Application (2020-2025) & (K Pcs)

Table 15. Global Sickle Cell Disease Drug Sale Market Share by Application (2020-2025)

Table 16. Global Sickle Cell Disease Drug Revenue by Application (2020-2025) & (\$ million)

Table 17. Global Sickle Cell Disease Drug Revenue Market Share by Application (2020-2025)

Table 18. Global Sickle Cell Disease Drug Sale Price by Application (2020-2025) & (USD/Pcs)

Table 19. Global Sickle Cell Disease Drug Sales by Company (2020-2025) & (K Pcs)

Table 20. Global Sickle Cell Disease Drug Sales Market Share by Company (2020-2025)

Table 21. Global Sickle Cell Disease Drug Revenue by Company (2020-2025) & (\$ millions)

Table 22. Global Sickle Cell Disease Drug Revenue Market Share by Company (2020-2025)

Table 23. Global Sickle Cell Disease Drug Sale Price by Company (2020-2025) & (USD/Pcs)

Table 24. Key Manufacturers Sickle Cell Disease Drug Producing Area Distribution and Sales Area

Table 25. Players Sickle Cell Disease Drug Products Offered

Table 26. Sickle Cell Disease Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global Sickle Cell Disease Drug Sales by Geographic Region (2020-2025) & (K Pcs)

Table 30. Global Sickle Cell Disease Drug Sales Market Share Geographic Region (2020-2025)

Table 31. Global Sickle Cell Disease Drug Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 32. Global Sickle Cell Disease Drug Revenue Market Share by Geographic Region (2020-2025)

Table 33. Global Sickle Cell Disease Drug Sales by Country/Region (2020-2025) & (K Pcs)

Table 34. Global Sickle Cell Disease Drug Sales Market Share by Country/Region (2020-2025)

Table 35. Global Sickle Cell Disease Drug Revenue by Country/Region (2020-2025) & (\$ millions)

Table 36. Global Sickle Cell Disease Drug Revenue Market Share by Country/Region (2020-2025)

Table 37. Americas Sickle Cell Disease Drug Sales by Country (2020-2025) & (K Pcs)

Table 38. Americas Sickle Cell Disease Drug Sales Market Share by Country (2020-2025)

Table 39. Americas Sickle Cell Disease Drug Revenue by Country (2020-2025) & (\$ millions)

Table 40. Americas Sickle Cell Disease Drug Sales by Type (2020-2025) & (K Pcs)

Table 41. Americas Sickle Cell Disease Drug Sales by Application (2020-2025) & (K Pcs)

Table 42. APAC Sickle Cell Disease Drug Sales by Region (2020-2025) & (K Pcs)

Table 43. APAC Sickle Cell Disease Drug Sales Market Share by Region (2020-2025)

Table 44. APAC Sickle Cell Disease Drug Revenue by Region (2020-2025) & (\$ millions)

Table 45. APAC Sickle Cell Disease Drug Sales by Type (2020-2025) & (K Pcs)

Table 46. APAC Sickle Cell Disease Drug Sales by Application (2020-2025) & (K Pcs)

Table 47. Europe Sickle Cell Disease Drug Sales by Country (2020-2025) & (K Pcs)

Table 48. Europe Sickle Cell Disease Drug Revenue by Country (2020-2025) & (\$ millions)

Table 49. Europe Sickle Cell Disease Drug Sales by Type (2020-2025) & (K Pcs)

Table 50. Europe Sickle Cell Disease Drug Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Sickle Cell Disease Drug Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Sickle Cell Disease Drug Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Sickle Cell Disease Drug Sales by Type (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Sickle Cell Disease Drug Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Sickle Cell Disease Drug
Table 56. Key Market Challenges & Risks of Sickle Cell Disease Drug
Table 57. Key Industry Trends of Sickle Cell Disease Drug
Table 58. Sickle Cell Disease Drug Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Sickle Cell Disease Drug Distributors List
Table 61. Sickle Cell Disease Drug Customer List
Table 62. Global Sickle Cell Disease Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. Global Sickle Cell Disease Drug Revenue Forecast by Region (2026-2031) & (\$ millions)
Table 64. Americas Sickle Cell Disease Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Sickle Cell Disease Drug Annual Revenue Forecast by Country (2026-2031) & (\$ millions)
Table 66. APAC Sickle Cell Disease Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Sickle Cell Disease Drug Annual Revenue Forecast by Region (2026-2031) & (\$ millions)
Table 68. Europe Sickle Cell Disease Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Sickle Cell Disease Drug Revenue Forecast by Country (2026-2031) & (\$ millions)
Table 70. Middle East & Africa Sickle Cell Disease Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Sickle Cell Disease Drug Revenue Forecast by Country (2026-2031) & (\$ millions)
Table 72. Global Sickle Cell Disease Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 73. Global Sickle Cell Disease Drug Revenue Forecast by Type (2026-2031) & (\$

millions)

Table 74. Global Sickle Cell Disease Drug Sales Forecast by Application (2026-2031) & (K Pcs)

Table 75. Global Sickle Cell Disease Drug Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 76. Acceleron Pharma Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 77. Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 78. Acceleron Pharma Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 79. Acceleron Pharma Inc Main Business

Table 80. Acceleron Pharma Inc Latest Developments

Table 81. Addmedica SAS Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 82. Addmedica SAS Sickle Cell Disease Drug Product Portfolios and Specifications

Table 83. Addmedica SAS Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 84. Addmedica SAS Main Business

Table 85. Addmedica SAS Latest Developments

Table 86. Angiocrine Bioscience Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 87. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 88. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 89. Angiocrine Bioscience Inc Main Business

Table 90. Angiocrine Bioscience Inc Latest Developments

Table 91. Annexin Pharmaceuticals AB Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 92. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolios and Specifications

Table 93. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 94. Annexin Pharmaceuticals AB Main Business

Table 95. Annexin Pharmaceuticals AB Latest Developments

Table 96. ArQule Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. ArQule Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 98. ArQule Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 99. ArQule Inc Main Business

Table 100. ArQule Inc Latest Developments

Table 101. Bio Products Laboratory Ltd Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

Table 103. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 104. Bio Products Laboratory Ltd Main Business

Table 105. Bio Products Laboratory Ltd Latest Developments

Table 106. Bioverativ Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Bioverativ Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 108. Bioverativ Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 109. Bioverativ Inc Main Business

Table 110. Bioverativ Inc Latest Developments

Table 111. bluebird bio Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. bluebird bio Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 113. bluebird bio Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 114. bluebird bio Inc Main Business

Table 115. bluebird bio Inc Latest Developments

Table 116. Bristol-Myers Squibb Co Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolios and Specifications

Table 118. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 119. Bristol-Myers Squibb Co Main Business

Table 120. Bristol-Myers Squibb Co Latest Developments

Table 121. Calimmune Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Calimmune Inc Sickle Cell Disease Drug Product Portfolios and

Specifications

Table 123. Calimmune Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 124. Calimmune Inc Main Business

Table 125. Calimmune Inc Latest Developments

Table 126. CRISPR Therapeutics Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolios and Specifications

Table 128. CRISPR Therapeutics Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 129. CRISPR Therapeutics Main Business

Table 130. CRISPR Therapeutics Latest Developments

Table 131. CSL Ltd Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. CSL Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

Table 133. CSL Ltd Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 134. CSL Ltd Main Business

Table 135. CSL Ltd Latest Developments

Table 136. Daiichi Sankyo Co Ltd Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

Table 138. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 139. Daiichi Sankyo Co Ltd Main Business

Table 140. Daiichi Sankyo Co Ltd Latest Developments

Table 141. Editas Medicine Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Editas Medicine Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 143. Editas Medicine Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 144. Editas Medicine Inc Main Business

Table 145. Editas Medicine Inc Latest Developments

Table 146. Errant Gene Therapeutics LLC Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolios

and Specifications

Table 148. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 149. Errant Gene Therapeutics LLC Main Business

Table 150. Errant Gene Therapeutics LLC Latest Developments

Table 151. Gamida Cell Ltd Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolios and Specifications

Table 153. Gamida Cell Ltd Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 154. Gamida Cell Ltd Main Business

Table 155. Gamida Cell Ltd Latest Developments

Table 156. Genethon SA Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Genethon SA Sickle Cell Disease Drug Product Portfolios and Specifications

Table 158. Genethon SA Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 159. Genethon SA Main Business

Table 160. Genethon SA Latest Developments

Table 161. Gilead Sciences Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 163. Gilead Sciences Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 164. Gilead Sciences Inc Main Business

Table 165. Gilead Sciences Inc Latest Developments

Table 166. Global Blood Therapeutics Inc Basic Information, Sickle Cell Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 167. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolios and Specifications

Table 168. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 169. Global Blood Therapeutics Inc Main Business

Table 170. Global Blood Therapeutics Inc Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Sickle Cell Disease Drug
- Figure 2. Sickle Cell Disease Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Sickle Cell Disease Drug Sales Growth Rate 2020-2031 (K Pcs)
- Figure 7. Global Sickle Cell Disease Drug Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Sickle Cell Disease Drug Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Sickle Cell Disease Drug Sales Market Share by Country/Region (2024)
- Figure 10. Sickle Cell Disease Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of ARQ-092
- Figure 12. Product Picture of BIVV-003
- Figure 13. Product Picture of CAL-H
- Figure 14. Product Picture of CTX-001
- Figure 15. Product Picture of DRX-194
- Figure 16. Product Picture of Others
- Figure 17. Global Sickle Cell Disease Drug Sales Market Share by Type in 2025
- Figure 18. Global Sickle Cell Disease Drug Revenue Market Share by Type (2020-2025)
- Figure 19. Sickle Cell Disease Drug Consumed in Hospital
- Figure 20. Global Sickle Cell Disease Drug Market: Hospital (2020-2025) & (K Pcs)
- Figure 21. Sickle Cell Disease Drug Consumed in Clinic
- Figure 22. Global Sickle Cell Disease Drug Market: Clinic (2020-2025) & (K Pcs)
- Figure 23. Sickle Cell Disease Drug Consumed in Others
- Figure 24. Global Sickle Cell Disease Drug Market: Others (2020-2025) & (K Pcs)
- Figure 25. Global Sickle Cell Disease Drug Sale Market Share by Application (2024)
- Figure 26. Global Sickle Cell Disease Drug Revenue Market Share by Application in 2025
- Figure 27. Sickle Cell Disease Drug Sales by Company in 2025 (K Pcs)
- Figure 28. Global Sickle Cell Disease Drug Sales Market Share by Company in 2025
- Figure 29. Sickle Cell Disease Drug Revenue by Company in 2025 (\$ millions)
- Figure 30. Global Sickle Cell Disease Drug Revenue Market Share by Company in 2025
- Figure 31. Global Sickle Cell Disease Drug Sales Market Share by Geographic Region

(2020-2025)

Figure 32. Global Sickle Cell Disease Drug Revenue Market Share by Geographic Region in 2025

Figure 33. Americas Sickle Cell Disease Drug Sales 2020-2025 (K Pcs)

Figure 34. Americas Sickle Cell Disease Drug Revenue 2020-2025 (\$ millions)

Figure 35. APAC Sickle Cell Disease Drug Sales 2020-2025 (K Pcs)

Figure 36. APAC Sickle Cell Disease Drug Revenue 2020-2025 (\$ millions)

Figure 37. Europe Sickle Cell Disease Drug Sales 2020-2025 (K Pcs)

Figure 38. Europe Sickle Cell Disease Drug Revenue 2020-2025 (\$ millions)

Figure 39. Middle East & Africa Sickle Cell Disease Drug Sales 2020-2025 (K Pcs)

Figure 40. Middle East & Africa Sickle Cell Disease Drug Revenue 2020-2025 (\$ millions)

Figure 41. Americas Sickle Cell Disease Drug Sales Market Share by Country in 2025

Figure 42. Americas Sickle Cell Disease Drug Revenue Market Share by Country (2020-2025)

Figure 43. Americas Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)

Figure 44. Americas Sickle Cell Disease Drug Sales Market Share by Application (2020-2025)

Figure 45. United States Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 46. Canada Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 47. Mexico Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 48. Brazil Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 49. APAC Sickle Cell Disease Drug Sales Market Share by Region in 2025

Figure 50. APAC Sickle Cell Disease Drug Revenue Market Share by Region (2020-2025)

Figure 51. APAC Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)

Figure 52. APAC Sickle Cell Disease Drug Sales Market Share by Application (2020-2025)

Figure 53. China Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 54. Japan Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 55. South Korea Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 56. Southeast Asia Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 57. India Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 58. Australia Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 59. China Taiwan Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 60. Europe Sickle Cell Disease Drug Sales Market Share by Country in 2025

Figure 61. Europe Sickle Cell Disease Drug Revenue Market Share by Country (2020-2025)

Figure 62. Europe Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)

Figure 63. Europe Sickle Cell Disease Drug Sales Market Share by Application (2020-2025)

Figure 64. Germany Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 65. France Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 66. UK Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 67. Italy Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 68. Russia Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 69. Middle East & Africa Sickle Cell Disease Drug Sales Market Share by Country (2020-2025)

Figure 70. Middle East & Africa Sickle Cell Disease Drug Sales Market Share by Type (2020-2025)

Figure 71. Middle East & Africa Sickle Cell Disease Drug Sales Market Share by Application (2020-2025)

Figure 72. Egypt Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 73. South Africa Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 74. Israel Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 75. Turkey Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 76. GCC Countries Sickle Cell Disease Drug Revenue Growth 2020-2025 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of Sickle Cell Disease Drug in 2025

Figure 78. Manufacturing Process Analysis of Sickle Cell Disease Drug

Figure 79. Industry Chain Structure of Sickle Cell Disease Drug

Figure 80. Channels of Distribution

Figure 81. Global Sickle Cell Disease Drug Sales Market Forecast by Region (2026-2031)

Figure 82. Global Sickle Cell Disease Drug Revenue Market Share Forecast by Region (2026-2031)

Figure 83. Global Sickle Cell Disease Drug Sales Market Share Forecast by Type (2026-2031)

Figure 84. Global Sickle Cell Disease Drug Revenue Market Share Forecast by Type (2026-2031)

Figure 85. Global Sickle Cell Disease Drug Sales Market Share Forecast by Application (2026-2031)

Figure 86. Global Sickle Cell Disease Drug Revenue Market Share Forecast by

Application (2026-2031)

I would like to order

Product name: Global Sickle Cell Disease Drug Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G113E5261383EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G113E5261383EN.html>